24 October 2017
News and Views
Links and Services
fiogf49gjkf04The most recent issue of the Alimentary Pharmacology & Therapeutics examined the efficacy of vedolizumab induction therapy for inflammatory bowel disease in clinical practice.
Vedolizumab is a humanised monoclonal IgG1 antibody targeting α4β7 integrin.<
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors